Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
White Blood Cells From Healthy Donors to Treat Solid Cancers
NCT00900497Phase 2Enrolling by invitation
- Start
- Apr 2009
- Primary completion
- Dec 2029
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of white blood cells + granulocytes in solid tumor. Primary endpoint: Objective Response Rate at 90 days. Started Apr 2009; status: enrolling by invitation.
02
Drugs
white blood cells + granulocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00900497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900497.